#biogen — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #biogen, aggregated by home.social.
-
A new sort of #Alzheimer’s #drug shows glimmers of promise
The experimental drug lowered tau levels and showed small improvements in memory loss
The compound, called #diranersen and developed by pharma giant #Biogen, reduced tau levels in patients’ cerebrospinal fluid by between 50 and 65 percent as compared with the start of the trial. The drug also seemed to slightly slow people people’s cognitive decline compared with those given a placebo.
https://www.sciencenews.org/article/new-alzheimers-drug-tau-promise
https://archive.ph/b4WEH -
ANTITRUST Biogen probed by Italy over MS drug competition cinquewnews.blogspot.com/2026/05/biog... #Antitrust #Biogen #MultipleSclerosis #MSDrug #PharmaNews #ItalianAntitrust #CompetitionLaw #HealthcareIndustry #Biotech #Natalizumab #Sandoz #DrugMarket #EUCompetition #Pharmaceuticals #MedicalNews
Biogen probed by Italy over MS... -
Why did Biogen pay up for Apellis Pharmaceuticals?
Because this may be less about buying a drug and more about buying a nephrology platform.
Our latest argues that kidney disease is starting to look like biotech’s next strategic battleground, and that Biogen’s Apellis deal may be an early signal of where the industry is heading.
Read more: https://biotech.industryexaminer.com/biogen-apellis-kidney-disease-nephrology-biotech/
-
Zimmer Biomet ($ZBH) reported EPS of $1.74, matching the forecast of $1.74. Revenue was $1.82B, slightly exceeding the expected $1.8B.
Global Payments ($GPN) achieved EPS of $3.08, just below the forecast of $3.09. Revenue reached $2.6B, surpassing the anticipated $2.38B.
Biogen ($BIIB) posted EPS of $4.08, exceeding the forecast of $3.77. Revenue was $2.47B, slightly above the expected $2.43B.
#Earnings #Q3 #ZimmerBiomet #GlobalPayments #Biogen #Investing #Finance #Stocks #MarketNews
-
Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years. https://www.japantimes.co.jp/news/2024/09/21/world/science-health/alzheimers-drugs-controversy/ #worldnews #sciencehealth #dementia #aging #alzheimer039s #eisai #biogen #elililly #drugs #medicine #brain
-
European Medicines Agency approves 14 new medicines but rejects new Alzheimer’s drug https://www.euractiv.com/section/health-consumers/news/european-medicines-agency-approves-14-new-medicines-but-rejects-new-alzheimers-drug/?utm_source=dlvr.it&utm_medium=mastodon #AlzheimersDisease #Biogen #Eisai #Leqembi #novonordisk
-
Moderna’s COVID-Flu combo shot beats separate vaccines in phase III study—FDA accepts Eisai's subcutaneous Leqembi filing, sets January 25 decision date — Boehringer, Lilly face off in MASH at EASL—http://bit.ly/w28kSd #moderna #vaccines #flu #covid19 #alzheimers #fda #eisai #biogen #elililly #mash #easl #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
-
Biogen to buy Human Immunology Biosciences in deal worth up to $1.8B—Boehringer pays OSE $42M to expand collab into cardio disease, grab new asset —9 top biopharma CEO-to-employee pay gaps --http://bit.ly/w28kSd #biogen #mergersandacquisitions #boehringeringelheim #cardiovasculardisease #pharmaceos #executivecompensation #paygap #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
-
J&J to buy Proteologix and its dual-targeting antibody drugs for $850M—Biogen walks away from Ionis-partnered ALS, Angelman prospects after peek at clinical data —FDA approves expanded use of Bristol Myers' cancer cell therapy --http://bit.ly/w28kSd #jnj #biogen #als #celltherapy #fda #bristolmyerssquibb #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
-
Novo Nordisk owner buys majority stake in Austrian life science tools company—As sales of weight loss drugs skyrocket, the insulin market falters —Eisai starts rolling submission for injectable version of Alzheimer's drug with FDA --http://bit.ly/w28kSd #novonordisk #mergersandacquisitions #insulin #diabetes #alzheimers #eisai #biogen #fda #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
-
About 3.6 mln Medicare beneficiaries could be eligible for Wegovy coverage, study shows—Biogen cost cuts drive profit beat, Alzheimer's drug sales jump —Enter Xaira, with $1bn for its AI in drug discovery platform--http://bit.ly/w28kSd #medicare #wegovy #novonordisk #biogen #earnings #drugdiscovery #ai #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
-
Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimer's, Eisai and Biogen's Leqembi is facing an unexpected hurdle to widespread use. https://www.japantimes.co.jp/news/2024/04/24/world/science-health/alzheimer-drug-us-adoption-slow/ #worldnews #sciencehealth #alzheimers #brain #eisai #biogen #leqembi #us
-
An expected news from Alzheimer therapies, https://www.alzforum.org/news/community-news/adieu-aduhelm-biogen-stops-marketing-antibody
A bit nostalgic, though, because I was one of the few whose cognition improved (relatively, i.e. compared to the control-group) during the years I got the antibody 10 mg / kg, enough for Biogen to apply for license.
It was a marvellous box-seat to observe pharmaceutical research with all it's intricacies, and live neurological expertise within an arm's reach was invaluable.
Here is the history of aducanumab, rest in pieces, https://www.alzforum.org/therapeutics/aduhelm
-
Biogen dumps dubious Alzheimer’s drug after profit-killing FDA scandal - Enlarge / The exterior of the headquarters of biotechnology company Bio... - https://arstechnica.com/?p=2000435 #clinicaltrial #aducanumab #alzheimers #science #aduhelm #health #biogen #fda
-
New Alzheimer's drug lecanemab will cost around ¥2.98 million per year in Japan, but will be largely covered by public health insurance that will limit the burden for patients to between 10% and 30% of that cost, subject to a cap, a health ministry body has said. https://www.japantimes.co.jp/news/2023/12/13/japan/eisai-biogen-alzheimers-drug-price/?utm_content=buffer4dd52&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #japan #alzheimer039s #drugs #eisai #biogen #pharmaceuticals
-
Massachusetts biopharma job growth surpasses that of other states -- Pfizer, playing catch-up with Novartis, bags FDA approval for drug combo in lung cancer -- Biogen lays off staffers at newly acquired Reata, with 113 set to lose positions -- See more on our front page news http://bit.ly/w28kSd #biotechhubs #massachusetts #pifzer #lungcancer #fda #biogen #layoffs #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
-
Sage's new #antidepressant is more like an antibiotic than an SSRI: it's taken for 14 days, then re-dosed as needed. But its long-term effectiveness is debatable.
Turns out, it's so rapid-acting that some psychiatrists don't even care. But will the #FDA?
My preview ahead of the FDA decision:
www.statnews.com/2023/07/31/sage-zuranolone-antidepressant-fda/#depression #sage #biogen #ssri #health #mentalhealth #healthcare #medicine #biotech #pharma
-
Some doctors said its effect on the disease may not be clinically meaningful enough when weighed against the risk of brain swelling, its likely high price. https://www.japantimes.co.jp/news/2023/06/19/world/science-health-world/europe-alzheimers-experts-doubt-eisai-biogen-drug/?utm_content=buffer28b58&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #news #worldnews #health #brain #alzheimers #biogen #eisai
-
Four senior #FDA leaders forged close ties with #Biogen ahead of #Aduhelm's approval. Now they've all left FDA. Three of those four senior officials, who managed and worked closely with the clinical and biostats reviewers assigned to the Aduhelm application, have now ended up working at drugmakers
https://endpts.com/four-senior-fda-leaders-forged-close-ties-with-biogen-ahead-of-aduhelms-approval-now-theyve-all-left-fda/ #revolvingdoor #quidproquo -
FDA approves new Alzheimer’s treatment despite risks, unclear benefits - Enlarge / MRI of a human brain. (credit: Getty | BSIP)
The Foo... - https://arstechnica.com/?p=1908494 #cognitivedecline #alzheimers #treatment #antibody #approval #science #biogen #eisai #fda
-
Congressional inquiry into 'highly atypical' #FDA-#Biogen ties ends with damning report, no repercussions, a slap on the wrist for both and a roadmap for how other companies may leverage behind-the-scenes interactions with FDA leaders to their advantage https://bit.ly/3Ckusy1
-
'Two US congressional committees have accused the Food and Drug Administration of inappropriately collaborating with Biogen before approving the company’s Alzheimer’s drug.'
#FDA #Alzheimer #Biogen #DrugDevelopment
https://www.ft.com/content/5389750b-71b0-4fe6-9793-feb6f64712e1
-
Dubious $56,000 Alzheimer’s drug spurs largest Medicare price hike ever - Enlarge / Biogen Inc. headquarters in Cambridge, Massachusetts. Biogen ... - https://arstechnica.com/?p=1813120 #alzheimersdisease #healthinsurance #healthcare #coverage #medicare #premiums #science #aduhelm #biogen #cms #fda
-
Ever forget stuff? You may have Alzheimer’s, says maker of $56K Alzheimer’s drug - Enlarge / The exterior of the headquarters of biotechnology company Biogen in Cam... - https://arstechnica.com/?p=1782649 #mildcognitiveimpairment #alzheimers #science #aduhelm #biogen #fda
-
Expert panel says new $56K Alzheimer’s drug is unproven—and worth $8,400 max - Enlarge / The exterior of the headquarters of biotechnology company Biogen in Cam... - https://arstechnica.com/?p=1781019 #alzheimersdisease #science #biogen #icer #fda
